ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Post-Mkt 07-08 16:01:33 EDT

2.02

+0.00

0.00%

盘后2.02

+0.000.00%

16:00 EDT

High2.11	Low1.96	Vol277.80K
Open2.02	D1 Closing2.02	Amplitude7.43%
Mkt Cap52.52M	Tradable Cap42.77M	Total Shares26.00M
T/O565.32K	T/O Rate1.31%	Tradable Shares21.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":2.02,"timestamp":1783540800000,"preClose":2.02,"halted":0,"volume":277796,"hourTrading":{"tag":"盘后","latestPrice":2.02,"preClose":2.02,"latestTime":"16:00 EDT","volume":85,"amount":171.7,"timestamp":1783540819990,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":21172300,"shares":26000400,"eps":-0.379546,"marketStatus":"Post-Mkt","change":0,"latestTime":"07-08 16:01:33 EDT","open":2.02,"high":2.11,"low":1.96,"amount":565318,"amplitude":0.074257,"askPrice":2.1,"askSize":4,"bidPrice":2.01,"bidSize":315,"shortable":3,"etf":0,"ttmEps":-0.379546,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1783555200000},"marketStatusCode":4,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":2.02,"preHourTrading":{"tag":"盘前","latestPrice":2.06,"preClose":2.02,"latestTime":"08:24 EDT","volume":7852,"amount":16061.949123999999,"timestamp":1783513479151,"change":0.04,"changeRate":0.019802,"amplitude":0.034653},"postHourTrading":{"tag":"盘后","latestPrice":2.02,"preClose":2.02,"latestTime":"16:00 EDT","volume":85,"amount":171.7,"timestamp":1783540819990,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.985875,"impliedVol":1.8394,"impliedVolPercentile":0.8506},"requestUrl":"/m/hq/s/ABVC/tweets","defaultTab":"tweets","newsList":[{"id":"2649672519","title":"Axsome Therapeutics: SUNOSI IP De-Risked, ADHD Phase 3 Expansion Supports Reaffirmed $290 12-Month Price Target and Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2649672519","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649672519?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:15","pubTimestamp":1783505743,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiter...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/axsome-therapeutics-sunosi-ip-de-risked-adhd-phase-3-expansion-supports-reaffirmed-290-12-month-price-target-and-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/axsome-therapeutics-sunosi-ip-de-risked-adhd-phase-3-expansion-supports-reaffirmed-290-12-month-price-target-and-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AXSM","ADHD","ABVC","IP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984983","title":"Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984983","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984983?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422000,"startTime":"0","endTime":"0","summary":"The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July  07, 2026  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/07/3323028/33090/en/Axsome-Therapeutics-Initiates-FOCUS-2-Phase-3-Trial-of-Solriamfetol-in-Children-with-Attention-Deficit-Hyperactivity-Disorder-ADHD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4585","BK4139","BK4007","BK4135","AXSM","ABVC","BK4505","ADHD","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649621431","title":"Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2649621431","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649621431?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:30","pubTimestamp":1783341000,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., July  06, 2026  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar TMS technology with direct patient care through","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/06/3322415/0/en/Neuronetics-to-Participate-in-a-Panel-Discussion-at-B-Riley-Securities-Mind-Muscle-Vision-Summit-on-July-16-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TMS","SMMF","ABVC","BK4211","STIM","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649619008","title":"The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2649619008","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649619008?lang=en_us&edition=fundamental","pubTime":"2026-07-06 04:19","pubTimestamp":1783282799,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc. recently reported dosing the first patient in its FOCUS-3 Phase 3 trial of solriamfetol for adolescents with ADHD, while also being added to multiple Russell large-cap and growth indices and removed from several small-cap indices.\nThis combination of a pivotal late-stage CNS trial in a new age group and a shift into larger-cap equity benchmarks may influence how investors think about Axsome’s clinical profile and market positioning.\nWe’ll now examine how the Phase 3...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/the-bull-case-for-axsome-therapeutics-axsm-could-change-foll-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/the-bull-case-for-axsome-therapeutics-axsm-could-change-foll-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","PTH","AXSM","ADHD","BK4585","BK4505","BK4007","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648638614","title":"ABVC Biopharma Replaces Auditor Simon & Edward with Kreit & Chiu for 2026 Audit","url":"https://stock-news.laohu8.com/highlight/detail?id=2648638614","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648638614?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:02","pubTimestamp":1783022538,"startTime":"0","endTime":"0","summary":"ABVC BioPharma replaces auditor Simon & Edward with Kreit & Chiu for 2026 auditABVC BioPharma replaced auditor Simon & Edward with Kreit & Chiu as independent accountant for fiscal 2026, effective Jun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL92MsRh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648500733","title":"Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®","url":"https://stock-news.laohu8.com/highlight/detail?id=2648500733","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648500733?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:30","pubTimestamp":1782995400,"startTime":"0","endTime":"0","summary":"CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional InvestorsKANSAS CITY, Kan., July  02, 2026  (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/02/3321301/0/en/Cingulate-Inc-NASDAQ-CING-Added-to-Russell-3000E.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SQQQ","IYW","QLD","PSQ","QQQJ","NVIW.SI","BK4139","JEPQ","ONEQ","CING","FTEC","BK4007","MNQmain","TQQY","ADHD","GPIQ","QQQM","QQQE","QID","NDX","QQQA","QYLG",".IXIC","QQQY","TQQQ","ABVC","TECS","NQmain","QDTE","QQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647376419","title":"BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2647376419","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647376419?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732600,"startTime":"0","endTime":"0","summary":"Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTS","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/29/3318863/17676/en/BrainsWay-Presents-Positive-Data-from-Largest-Real-World-Study-of-Deep-TMS-in-Patients-with-Comorbid-PTSD-and-Major-Depressive-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","TMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646952339","title":"BlinkLab Says European ADHD Study Completes Participant Recruitment, Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646952339","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646952339?lang=en_us&edition=fundamental","pubTime":"2026-06-26 13:58","pubTimestamp":1782453519,"startTime":"0","endTime":"0","summary":"BlinkLab (ASX:BB1) said its European attention-deficit/hyperactivity disorder (ADHD) study, being conducted in collaboration with Mental Care Group, completed participant recruitment and the firm's ne","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BB1.AU","ABVC","BK4139","EPV","BK7094","ADHD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646384202","title":"BlinkLab Nears Final Analysis in European ADHD Study After Completing Data Collection","url":"https://stock-news.laohu8.com/highlight/detail?id=2646384202","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646384202?lang=en_us&edition=fundamental","pubTime":"2026-06-26 07:37","pubTimestamp":1782430675,"startTime":"0","endTime":"0","summary":"Blinklab Limited ( ($AU:BB1) ) has shared an update. BlinkLab Limited has completed recruitment and neurometric data collection for its European at...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/blinklab-nears-final-analysis-in-european-adhd-study-after-completing-data-collection?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/blinklab-nears-final-analysis-in-european-adhd-study-after-completing-data-collection?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABVC","ADHD","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645722837","title":"Analyst Raises 12‑Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment","url":"https://stock-news.laohu8.com/highlight/detail?id=2645722837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645722837?lang=en_us&edition=fundamental","pubTime":"2026-06-23 23:05","pubTimestamp":1782227149,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Michael Okunewitch has maintained their bullish stance on DFTX stock, giving a Buy rating today. Michael Okunewitch has given h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-raises-12month-target-and-reiterates-buy-on-definium-after-best-in-class-mdd-trial-results-and-reduced-risk-adjustment-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-raises-12month-target-and-reiterates-buy-on-definium-after-best-in-class-mdd-trial-results-and-reduced-risk-adjustment-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645076482","title":"Brisebois Raises Definium Therapeutics Price Target to $63 on Strong DT120 ODT Phase 3 Data and Reduced MDD/GAD Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2645076482","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645076482?lang=en_us&edition=fundamental","pubTime":"2026-06-22 23:55","pubTimestamp":1782143746,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Francois Brisebois has reiterated their bullish stance on DFTX stock, giving a Buy rating today. Francois Brisebois has giv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/brisebois-raises-definium-therapeutics-price-target-to-63-on-strong-dt120-odt-phase-3-data-and-reduced-mdd-gad-risk-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/brisebois-raises-definium-therapeutics-price-target-to-63-on-strong-dt120-odt-phase-3-data-and-reduced-mdd-gad-risk-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODT","ABVC","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640435559","title":"Cingulate Faces FDA Delay But Maintains ADHD Drug Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2640435559","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640435559?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:32","pubTimestamp":1780403558,"startTime":"0","endTime":"0","summary":"Cingulate Inc ( ($CING) ) has shared an update. On June 2, 2026, Cingulate announced that the U.S. Food and Drug Administration issued a Complete R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cingulate-faces-fda-delay-but-maintains-adhd-drug-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cingulate-faces-fda-delay-but-maintains-adhd-drug-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","ADHD","ABVC","LABU","BK4585","CING","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910025","title":"Cingulate Receives Complete Response Letter from FDA for CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910025","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910025?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401600,"startTime":"0","endTime":"0","summary":"No Clinical Safety or Efficacy Concerns Currently IdentifiedAgency Feedback Primarily Focused on CMC-Related RequestsCompany Plans Prompt Response and Submission of Requested InformationCompany is Wel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305119/0/en/Cingulate-Receives-Complete-Response-Letter-from-FDA-for-CTx-1301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMC","IE00B1BXHZ80.USD","LU2237443895.HKD","LU2237443549.SGD","LU2237443465.HKD","LU2237443622.USD","LABU","BK4588","LU0882574139.USD","IE00BFXG1179.USD","LU0267386448.USD","LU2237443382.USD","LU2746668461.USD","ABVC","IE00BZ1G4Q59.USD","ADHD","LU1363072403.SGD","BK4006","LU2746668974.SGD","IE00BKVL7J92.USD","LU0971096721.USD","IE00BHPRN162.USD","LU0149725797.USD","LU0170899867.USD","BK4139","BK4585","BK4007","LU2237443978.SGD","CING"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636381833","title":"Collegium Pharma Leans on ADHD to Drive Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2636381833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636381833?lang=en_us&edition=fundamental","pubTime":"2026-05-20 13:15","pubTimestamp":1779254102,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical Inc. (($COLL)) has held its Q1 earnings call. Read on for the main highlights of the call. Collegium Pharmaceutical’s late...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/collegium-pharma-leans-on-adhd-to-drive-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/collegium-pharma-leans-on-adhd-to-drive-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADHD","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079367","title":"ABVC BioPharma Q1 EPS $(0.06), Same YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079367","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079367?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:26","pubTimestamp":1779110808,"startTime":"0","endTime":"0","summary":"ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.06) per share. This is unchanged from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52632789/abvc-biopharma-q1-eps-0-06-same-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636183020","title":"ABVC Biopharma Q1 FY26 net loss widens 79% to $1.69 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2636183020","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636183020?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:23","pubTimestamp":1779103412,"startTime":"0","endTime":"0","summary":"ABVC Biopharma posted a net loss of $1.69 million for the three months ended March 31, 2026, widening 79% from a year earlier, while revenue was unchanged at no revenue.Operating loss widened to $1.57 million as operating expenses more than doubled to $1.57 million on higher stock-based compensation.Net interest expense narrowed to $45,612, down 78%, reflecting lower interest expense tied to converted notes.Working capital deficit widened to $4.74 million, while net cash used in operating activities increased 66% to $894,243.Management highlighted full repayment of the Lind Notes, ongoing efforts to collect licensing and collaboration amounts due, and plans to seek additional financing while managing expenses amid going-concern uncertainty.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL8bptrp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635584660","title":"ABVC BioPharma delays filing quarterly report for period ended March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635584660","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635584660?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:04","pubTimestamp":1778879076,"startTime":"0","endTime":"0","summary":"ABVC BioPharma filed a Form 12b-25 late notice for its quarterly report for period ended March 31, 2026.Form 10-Q missed deadline as management was unable to finalize report and XBRL exhibit without unreasonable effort or expense.Filing targeted within SEC extension window of five calendar days following prescribed due date.Notice indicated no expected significant change in results of operations versus corresponding prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2026, and is solely responsible f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDLnMYsZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635125427","title":"Press Release: Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2635125427","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635125427?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760000,"startTime":"0","endTime":"0","summary":"KANSAS CITY, Kan., May 14, 2026  -- Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release  drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.\"Cingulate remains focused on disciplined execution in 2026 and we believe we are well positioned to bring our lead ADHD asset, CTx-1301, to market,\" said Cingulate CEO Shane J. Schaffer. \"We continue to engage constructively with the FDA on our new drug application while advancing commercial readiness and manufacturing capabilities, and believe our current resources provide an extended cash runway into 2027.\". process validation batch preparation for CTx-1301, which will serve as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4007","BK4585","TM","BK4604","ABVC","CING","BK4588","BK4555","BK4139","ADHD","BK4099","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634021113","title":"Collegium Pharmaceutical Completes AZSTARYS ADHD Business Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2634021113","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634021113?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:33","pubTimestamp":1778589207,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical ( ($COLL) ) has provided an update. On May 12, 2026, Collegium Pharmaceutical completed its previously announced $650 mill...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/collegium-pharmaceutical-completes-azstarys-adhd-business-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/collegium-pharmaceutical-completes-azstarys-adhd-business-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ABVC","ADHD","BK4139","COLL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634928215","title":"Press Release: Collegium Completes Acquisition of AZSTARYS(R) from Corium Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2634928215","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634928215?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:31","pubTimestamp":1778585460,"startTime":"0","endTime":"0","summary":"-- Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio --. -- Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 --. -- Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition --. -- 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million --. \"We are pleased to complete the acquisition of AZSTARYS, a highly strategic addition to our portfolio that strengthens our position in ADHD and further reinforces our long-standing commitment to improving patient care and delivering shareholder value,\" said Vikram Karnani, President and Chief Executive Officer. \"AZSTARYS is a complementary and differentiated therapy that expands the treatment options we can offer patients and prescribers, and we look forward to rapidly integrating it into our existing comm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADHD","BK4539","R","BK4022","ABVC","COLL","BK4007","BK4232","CNS","BK4135","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":0.2785},{"period":"1month","weight":0.5188},{"period":"3month","weight":0.4225},{"period":"6month","weight":-0.1022},{"period":"1year","weight":-0.4937},{"period":"ytd","weight":-0.0516}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0138},{"period":"3month","weight":0.1061},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.2047},{"period":"ytd","weight":0.0965}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.072395},{"month":2,"riseRate":0.125,"avgChangeRate":-0.057705},{"month":3,"riseRate":0.625,"avgChangeRate":0.040736},{"month":4,"riseRate":0.375,"avgChangeRate":0.01167},{"month":5,"riseRate":0.5,"avgChangeRate":0.035623},{"month":6,"riseRate":0.375,"avgChangeRate":1.167092},{"month":7,"riseRate":0.5,"avgChangeRate":-0.050324},{"month":8,"riseRate":0.5,"avgChangeRate":-0.054488},{"month":9,"riseRate":0.375,"avgChangeRate":-0.065685},{"month":10,"riseRate":0.375,"avgChangeRate":-0.067045},{"month":11,"riseRate":0.625,"avgChangeRate":0.051458},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012195}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction